Orbital Atherectomy for Treating De Novo, Severely Calcified Coronary Lesions: 3-Year Results of the Pivotal ORBIT II Trial

The presence of heavy coronary artery calcification increases the complexity of percutaneous coronary intervention (PCI) and increases the incidence of major adverse cardiac events (MACE): death, myocardial infarction (MI), target vessel revascularization (TVR), and stent thrombosis. The ORBIT II (Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions) trial reported low rates of procedural, 30-day, 1-year, and 2-year ischemic complications after treatment of de novo, severely calcified lesions with the Diamondback 360 ° Coronary Orbital Atherectomy System (OAS) (Cardiovascular Systems, Inc.).

Source: Cardiovascular Revascularization Medicine - January 22, 2017 Category: Cardiology Authors: Michael Lee, Philippe G énéreux, Richard Shlofmitz, Daniel Phillipson, Bynthia M. Anose, Brad J. Martinsen, Stevan I. Himmelstein, Jeff W. Chambers Source Type: research